Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
To find the best dose of ADI-PEG20 that can be given in combination with carboplatin and cabazitaxel to patients with AVPC.
Trial Details
- NCT ID
- NCT06085729
- Phase
- PHASE1 / PHASE2
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Cancer Type
- Prostate Cancer
- Interventions
- ADI-PEG 20
- Cabazitaxel
- Carboplatin
- Locations (sample)
- Houston, Texas, United States|29.76328,-95.36327
Key Eligibility Criteria
- Completion of informed consent prior to any study specific procedures.
- Patients must agree to tissue collection for correlative studies at the specified timepoints.
- Patients must consent to the MD Anderson Immunotherapy Platform laboratory protocol PA13-0291.
- Male aged 18 years and above.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Prostate Cancer Trials on Trialify →